Evidence-based medications for the treatment of the inflammatory bowel diseases

Current Opinion in Gastroenterology

Volumn 22, Issue 4, 2006, Pages 365-369

  De La Rue, Sarah A ^a   Bickston, Stephen J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Crohn's disease; Evidence based medicine; Infliximab; Therapy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE;

BONE PAIN; CANCER RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COLORECTAL CANCER; CROHN DISEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; INJECTION SITE REACTION; INNATE IMMUNITY; MEDICAL DECISION MAKING; MEDICAL EXPERT; PATIENT CARE; REMISSION; REVIEW; RISK REDUCTION; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 33746220260     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000231809.10773.c7     Document Type: Review

References (26)

1. Greer N, Mosser G, Logan G, Halaas GW. A practical approach to evidence grading. Jt Comm J Qual Improv 2000; 26:700-712.
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249-266.
3. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847-869.
4. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104:1293-1301.
5. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2:379-388.
6. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:363-371.
7. Sandborn WJ, Lofberg R, Reagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100:1780-1787. This is a cogent analysis that supports longer treatment duration with budesonide.
8. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005; 22:1-16. This review provides an excellent overview of the data while offering guidance for clinical management.
9. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302:981-987.
10. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37:674-678.
11. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105:367-372.
12. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66:916-922.
13. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;CD000545.
14. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-1785.
15. Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, et al. Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol 2003; 38:1050-1054.
16. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004; CD003574.
17. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99:91-96.
18. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333; quiz 591. This study of a fully human anti-TNF agent showed a dose-response curve in inducing remission.
19. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352:2193-2201. This randomized, controlled trial supported further attention to agents targeting innate immunity.
20. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143:895-904. This paper gives insight into current and future targets for therapy.
21. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100:2478-2485. This study supported dose escalation with this form of mesalamine, likely generalizable to other formulations.
22. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451-459.
23. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54:1573-1578. The size of this study is substantial, though not population-based.
24. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100:1539-1546.
25. Adam B, Liebregts T, Holtmann G. Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine [in German]. Z Gastroenterol 2006; 44:267-269.
26. Rutgeerts P, Sandborn WJ, Reagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476. This pivotal study supported the role of infliximab for ulcerative colitis and widened the possible uses of an anti-TNF approach to this disease.